Family Site

The contents provided by this page is intended for patients prescribed with Remsima® subcutaneous(SC). If you are an Australian Healthcare Professional , please click the relevant button.

Dosing Administration Device FAQs Safety Information

Device

Device Info

    Characteristics

    2-STEP simple operation 1

    LATEX FREE for patients with allergies 1,2

    29-GAUGE/5-BEVEL needle with less pain 2,3,4

    CITRATE FREE for less pain 1

    UP TO 28 DAYS available outside the fridge 1

    Characteristics

    PASSIVE ACTIVATION for patients who prefer manual injection control 1

    29-GAUGE/5-BEVEL needle with less pain 2,3,4

    BUILT-IN NEEDLE GUARD to protect from needlestick after injection 1

    LATEX FREE for patients with allergies 1,2

    CITRATE FREE for less pain 1

    UP TO 28 DAYS available outside the fridge 1

References

1. Remsima® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/Remsima®-epar-product-information_en.pdf Accessed 4 Sep 2020.

2. Celltrion Healthcare. Data on File. 2020

3. Glenski, Stephen, and Jill Conner. “29 gauge needles improve patient satisfaction over 27 gauge needles for daily glatiramer acetate injections.” Drug, healthcare and patient safety vol. 1 (2009): 81-6. doi:10.2147/dhps.s8495

4. Jaber, Amer et al. “A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis.” BMC neurology vol. 8 38. 10 Oct. 2008, doi:10.1186/1471-2377-8-38

Abbreviations

SC, subcutaneous